While inhibition of IL-6 with tocilizumab appears to be efficacious and safe in preliminary investigation, the results of several ongoing clinical trials should be wait to better define the role of tocilizumab in COVID-19 prior to routine clinical application (7). Here, IL6 is linked to COVID-19.